Phenotypes associated with this allele

• Allele Symbol: Ace2^tm1Hira
• Allele Name: targeted mutation 1, Hiromi Rakugi
• Allele ID: MGI:3794966
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
ot1	Ace2^tm1Hira/Y	involves: 129S7/SvEvBrd * C57BL/6	MGI:3804205

Genotype
MGI:3804205

ot1

• Allelic Composition: Ace2^tm1Hira/Y
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:135766 )

♂ • two-thirds of males die of congestive heart failure within 30 days of transverse aortic constriction (TAC) compared to one-third of wild-type males

growth/size/body

increased heart weight ( J:135766 )

♂ • two weeks after TAC, there is an increased gain in the heart weight to body weight ratio compared to wild-type males

increased lung weight ( J:135766 )

♂ • there is a significant increase in lung weight normalized to body weight two weeks after TAC compared to wild-type males receiving the same treatment

cardiovascular system

pulmonary vascular congestion ( J:135766 )

♂ • TAC leads to pulmonary congestion in 46% of males compared to 13% of males in controls

increased heart weight ( J:135766 )

♂ • two weeks after TAC, there is an increased gain in the heart weight to body weight ratio compared to wild-type males

dilated heart left ventricle ( J:135766 )

♂ • two weeks after TAC, the left ventricle is much more dilated than in wild-type males receiving TAC

♂ • left ventricle dimensions as measured by echocardiography confirm significant dilation

cardiac fibrosis ( J:135766 )

♂ • perivascular fibrosis occurs in males two weeks after TAC but not in control males

cardiac interstitial fibrosis ( J:135766 )

♂ • occurs in males two weeks after TAC while not occurring in controls

decreased ventricle muscle contractility ( J:135766 )

♂ • ventricular contractility is decreased more so than in wild-type males two weeks after TAC with a fractional shortening of 31 compared to 36% in wild-type males

♂ • dp/dt measurements are 15% lower than in wild-type males two weeks after TAC

congestive heart failure ( J:135766 )

♂ • two-thirds of males die of congestive heart failure within 30 days of TAC compared to one-third of wild-type males

respiratory system

pulmonary vascular congestion ( J:135766 )

♂ • TAC leads to pulmonary congestion in 46% of males compared to 13% of males in controls

increased lung weight ( J:135766 )

♂ • there is a significant increase in lung weight normalized to body weight two weeks after TAC compared to wild-type males receiving the same treatment

homeostasis/metabolism

increased angiotensin II level ( J:135766 )

• males have greater increases in angiotensin II levels in the heart tissue two weeks after TAC compared to similarly treated wild-type males

• mutant males had left ventricle levels of angiotensin II rise 7.5 fold after TAC while wild-type males only had a 5-fold rise in angiotensin II after TAC

increased circulating angiotensin II level ( J:135766 )

♂ • males have greater increases in angiotensin II levels in serum two weeks after TAC compared to similarly treated wild-type males

muscle

decreased ventricle muscle contractility ( J:135766 )

♂ • ventricular contractility is decreased more so than in wild-type males two weeks after TAC with a fractional shortening of 31 compared to 36% in wild-type males

♂ • dp/dt measurements are 15% lower than in wild-type males two weeks after TAC

cellular

cardiac interstitial fibrosis ( J:135766 )

♂ • occurs in males two weeks after TAC while not occurring in controls